Therefore, tyrosine kinase inhibitors (TKIs) such as imatinib were developed as ATP competitive inhibitors of the bcr-abl tyrosine kinase fusion protein for CML therapy [2]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.